Organizations
Conferences
Info & Opinion
January 8, 2009
The peer-reviewed journal PLoS Clinical Trials has a fascinating exchange of letters relating to drug safety, IRBs, DSMBs and public perceptions of clinical trial governance. A Cleveland Clinic broadside against the NIH.
The U.S. Senate began discussion of a bill to beef up spending on drug safety. UPI reports that a new $30 million program would be used for surveillance of drug safety issues. That would be part of a new total…
A leading cardiologist at the Cleveland Clinic, Steve Nissen, is charging that the NIH had a panic attack and should have allowed the ADAPT trial to continue. The ADAPT trial, for the newcomers, was the Alzheimer’s Disease Anti-Inflammatory Prevention Trial.…